Data from EMA (European Medicines Agency) - Curated by Marshall Pearce - Last updated 29 September 2017

Indication(s)

Ucedane is indicated in treatment of hyperammonaemia due to N-acetylglutamate synthase primary deficiency.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Hyperammonaemia

Hyperammonaemia

Hyperammonaemia can result in serious neurological damage or death. Could you recognise the signs and symptoms?

+ 2 more

ALP Lab Assessment

ALP Lab Assessment

Discover and overview of hypophosphatasia and details required to facilitate the timely and accurate detection of low alkaline phosphatase.

Fabry Disease

Fabry Disease

Explore the pathophysiology and treatment options for Fabry disease, a deficiency of the lysosomal enzyme alpha-galactosidase A

Load more

Related Content

More information

Category Value
Agency product number EMEA/H/C/004019
Orphan designation No
Date First Approved 23-06-2017
Type Medicinal product subject to restricted medical prescription
Marketing authorisation holder

Lucane Pharma